Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Provide patients with serious AdV infection or disease access to treatment with BCV.

Details

• Lead Sponsor: Chimerix
• Treatments: Brincidofovir

Criteria

Inclusion Criteria:

• Confirmed serious AdV infection based on clinical symptoms and laboratory testing showing AdV in the blood or other bodily fluids

• Able to swallow medication, either tablet or liquid

Exclusion Criteria:

• Previous dosing with Brincidofovir

• If female, not pregnant or trying to become pregnant